According to AstraZeneca's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.65265. At the end of 2022 the company had a P/S ratio of 4.74.
Year | P/S ratio | Change |
---|---|---|
2022 | 4.74 | -2.19% |
2021 | 4.85 | -1.45% |
2020 | 4.92 | -8.31% |
2019 | 5.37 | 25.56% |
2018 | 4.27 | 10.21% |
2017 | 3.88 | 29.36% |
2016 | 3.00 | -14.32% |
2015 | 3.50 | 1.95% |
2014 | 3.43 | 19.09% |
2013 | 2.88 | 37.53% |
2012 | 2.10 | 17.67% |
2011 | 1.78 | -8.96% |
2010 | 1.96 | -5.78% |
2009 | 2.08 | 10.47% |
2008 | 1.88 | -10.96% |
2007 | 2.11 | -31.88% |
2006 | 3.10 | -4.92% |
2005 | 3.26 | 16.72% |
2004 | 2.79 | -35.74% |
2003 | 4.35 | 27.74% |
2002 | 3.40 | -1.57% |
2001 | 3.46 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 4.96 | 6.67% | ๐บ๐ธ USA |
![]() Novartis NVS | 3.35 | -27.96% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 2.25 | -51.65% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 3.86 | -17.12% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 11.0 | 137.40% | ๐บ๐ธ USA |
![]() Sanofi SNY | 2.56 | -45.01% | ๐ซ๐ท France |
![]() Biogen BIIB | 3.72 | -20.02% | ๐บ๐ธ USA |
![]() Merck MRK | 4.47 | -3.90% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 3.06 | -34.30% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 1.84 | -60.49% | ๐ฌ๐ง UK |